Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (184 reviews)

For research use only.

Catalog No.S2807 Synonyms: GSK2118436A

184 publications

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436, GSK2118436A) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 184 publications

Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3

PubMed: 33619394 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1747

PubMed: 33741929 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(8):4421-4440

PubMed: 33849069 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-020-01628-x

PubMed: 33500549 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):85

PubMed: 33446653 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Biomolecules, 2021, 11(2)153

PubMed: 33503908 ( click the link to review the publication )

Front Oncol, 2021, 11:656453

PubMed: 33898322 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(4)1801

PubMed: 33670365 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)14

PubMed: 33649790 ( click the link to review the publication )

J Physiol Biochem, 2021, 10.1007/s13105-021-00789-x

PubMed: 33587254 ( click the link to review the publication )

Cancer Immunol Res, 2021, 10.1158/2326-6066.CIR-20-0905

PubMed: 33653716 ( click the link to review the publication )
Mol Carcinog, 2021, 60(3):201-212

PubMed: 33595872 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

EMBO Rep, 2020, e50163

PubMed: 33369872 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2981

PubMed: 33066704 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )

ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )
Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Vet Pathol, 2020, 300985820967449

PubMed: 33205710 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31105-31113

PubMed: 33229534 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )
ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )
Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )
Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )
Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )
J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	M4XMPWtqdmG\|ZTDBd5NigQ>?				MofKTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd{B1[WepZXSgRk1T[WZiVk[wNGUhdXW2YX70JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMh[29vZYjwdoV{e2mwZzDDSGM{PyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBjcW:2aX75cIF1\WRvTVXLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHL5JGFteGijU3Py[YVvKGG\|c3H5JJdqfGhiSVO1NEBw\iByLkCwNFch\|ryP	MlLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
SK-MEL-28	MmrRT4lv[XOnIFHzd4F6		NGP4b3oyKGh?		M2HGcGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIGPLMW1GVC1{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBGWkticHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxPCEQvF2=	M{TXNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
HepG2	MkTOT4lv[XOnIFHzd4F6				MoPiTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMESg{txO	NX\RbW17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzNpPkK0PVAxPjd\|PD;hQi=>
COLO205	Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9{MEWgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1?	NF20U3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
HepG2	MWTGeY5kfGmxbjDBd5NigQ>?		MXG0OUBucW5?	NVTHPWFPTE2VTx?=	NHrNV4JKdmirYnn0bY9vKG:oIFHsb\|UhcW5iVFfGMYJmfGFvc4TpcZVt[XSnZDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVbXHkNkBxcG:\|cHjvdplt[XSrb36geJJm[XSnZDDmc5IhPDVibXnud{BxemmxcjD0c{BVT0ZvYnX0ZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCjZoTldkA3OCCvaX7zJIJ6KG:meYPz[Zkh[myxdDDzZ4FvdmW{IHHuZYx6e2m\|IIfpeIghUUN3MDDv[kA{NjdizszN	MkDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
HFF	NWiwVnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUSxNEDPxE1?	NFvDeWE4OiCq	NIrTVVhFVVOR	NGjN[mNKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiaIXtZY4hUE[IIHPlcIx{KGijcnLvdolv\yC5aXzkJJR6eGViQj3SZYYhf2m2aDDJR\|UxKG:oIEOg{txO	M4DOXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
SK-MEL-28	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\iU\|ExKM7:TR?=	NU\qRoNIPzJiaB?=	NH7Wd3FFVVOR	MYTJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hW0tvTVXMMVI5KGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPDNizszN	M2X3VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A375P-F11	NV;ZZWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXvW2xtOTBizszN	MVK3NkBp	MXTEUXNQ	NU[yN5JoUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIFGzO\|VRNUZzMTDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEexJO69VQ>?	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MALME-3M	M2DJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PHN\|ExKM7:TR?=	NEm5cZo4OiCq	M3G0dmROW09?	NETl[41KSzVyPUGgcm0>	Ml;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
UACC-62	NGi2V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLENVAh\|ryP	NXzVToQ4PzJiaB?=	NYm5XXFmTE2VTx?=	MnvDTWM2OD1zIH7N	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
C32TG	NHizZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjnSGlCOTBizszN	NX;RdVJDPzJiaB?=	M{jrTWROW09?	NGnKVXdKSzVyPUGgcm0>	Mlu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-MEL-1	NGXqZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHLOFVHOTBizszN	NU\KfFR{PzJiaB?=	NYTHS2ZCTE2VTx?=	M{TMWmlEPTB;MjDuUS=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
M14	NFzUeo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLtNoxrOTBizszN	NXOzPI5oPzJiaB?=	NY\hS3A6TE2VTx?=	M3:1UmlEPTB;MjDuUS=>	NGXwSYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-28	NUDK[IV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe1W\|Q3OTBizszN	NXnSeJRLPzJiaB?=	NFX6V4RFVVOR	MVLJR\|UxRTNibl2=	NFfxUWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A375	NHjUVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	MlzsO\|IhcA>?	NFvKSW5FVVOR	MnTUTWM2OD12IH7N	M3TXW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DU-4475	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTPfGFiOTBizszN	MXW3NkBp	M2TaR2ROW09?	M2PrT2lEPTB;NTDuUS=>	NVfIUlh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UACC-257	NVTnWFJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXaNVAh\|ryP	NIXScGk4OiCq	NGj1NWxFVVOR	NV;wdXNXUUN3ME22JI5O	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Colo 205	M{XqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;RNVAh\|ryP	NHvO[HQ4OiCq	MnnqSG1UVw>?	M4PIUWlEPTB;NzDuUS=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-MEL-3	NGTPelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2WwdVExKM7:TR?=	NWXNe2NbPzJiaB?=	NV7FOnJITE2VTx?=	MkTBTWM2OD15IH7N	NXzxPGI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SH-4	M37L[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWWxNEDPxE1?	MWS3NkBp	MknXSG1UVw>?	NEfydpRKSzVyPUigcm0>	MoLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A101D	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmxNEDPxE1?	NFS5e\|A4OiCq	MkLrSG1UVw>?	NUC0cWN[UUN3ME25JI5O	MkHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ES-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILoXFIyOCEQvF2=	MVq3NkBp	M2raO2ROW09?	NFnqRYdKSzVyPUWzJI5O	M2D5SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HT-29	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2qwSFExKM7:TR?=	M3rTNFczKGh?	Ml\FSG1UVw>?	M3Th[WlEPTB;Nk[gcm0>	Ml7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW1417	M4PXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Tvc\|ExKM7:TR?=	M2ezN\|czKGh?	NV\ze49DTE2VTx?=	MmnUTWM2OD1zNUigcm0>	M4XMZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW872	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nrV\|ExKM7:TR?=	M1HJelczKGh?	MUPEUXNQ	M2W0SWlEPTB;M{e3JI5O	M1vxblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RKO	M3P4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUexNEDPxE1?	M1\CeFczKGh?	NX;OOFN6TE2VTx?=	NXvxZpdTUUN3ME2yMlUzOiEQvF2=	NV:3RlhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A673	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGxNEDPxE1?	NXzx[YRYPzJiaB?=	M2nkcmROW09?	Mkj5TWM2OD1zMDFOwG0>	NUXnXZRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
GCT	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInCdIkyOCEQvF2=	NX[xb4Y1PzJiaB?=	M1HDbWROW09?	M2TtT2lEPTB;MUCg{txO	NUPHPHloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
WM-115	MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4KwNlExKM7:TR?=	NFv4VZQ4OiCq	M4DrRmROW09?	M4nvc2lEPTB;NTDuUS=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
YUMAC	NV[0ZlZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLhNVAh\|ryP	M2H4ZVczKGh?	MoLDSG1UVw>?	NYPGSYZ7UUN3ME21JI5O	MmLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
OV-90	M3jTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrnboEyOCEQvF2=	MXK3NkBp	NVjKdZZuTE2VTx?=	MWXJR\|UxRTJ7IH7N	M4jRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H508	M3\W[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\jNVAh\|ryP	M4DyW\|czKGh?	NHr2XYNFVVOR	MkjoTWM2OD1zMDFOwG0>	NV3YeHpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MDA-MB-231	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHn4d4YyOCEQvF2=	MYC3NkBp	MljESG1UVw>?	NUXod2s1UUN3ME2xNEDPxE1?	MmjrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW756	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHBVXEyOCEQvF2=	M{jGUVczKGh?	NVTMWo9jTE2VTx?=	NWXMO4J2UUN3ME2xNEDPxE1?	NIPBdHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW-837	NGTJW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXJNVAh\|ryP	MYi3NkBp	MWPEUXNQ	MnzGTWM2OD1zMDFOwG0>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
UMUC-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\4RlExKM7:TR?=	M3LycFczKGh?	NXPT[mxwTE2VTx?=	NX74[JFkUUN3ME2xNEDPxE1?	NWPjT3BERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
LS-174T	M{[z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHFNVAh\|ryP	NVjQe5dFPzJiaB?=	MXrEUXNQ	NXjnN45yUUN3ME2xNEDPxE1?	NGnxT4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A549	M1rJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnaVnFIOTBizszN	MoPUO\|IhcA>?	NFjYeoVFVVOR	MnLlTWM2OD1zMDFOwG0>	M{C1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SHP-77	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVexNEDPxE1?	MlXDO\|IhcA>?	MV\EUXNQ	M{TWT2lEPTB;MUCg{txO	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW480	NFPWd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37ZdVExKM7:TR?=	NITUWYs4OiCq	Mn:wSG1UVw>?	Ml;GTWM2OD1zMDFOwG0>	MonyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DLD-1	M{jtc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVexNEDPxE1?	NHPoUWg4OiCq	MmOxSG1UVw>?	NEDzPJZKSzVyPUGwJO69VQ>?	NFTkbW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HCT-116	NHzVU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXXbWsyOTBizszN	MlTpO\|IhcA>?	NX\CfFV1TE2VTx?=	MlWwTWM2OD1zMDFOwG0>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H747	NILDZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PuWVExKM7:TR?=	NGHFXnQ4OiCq	M13p[GROW09?	NYXORnIyUUN3ME2xNEDPxE1?	NF7OdVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
T-84	M3XSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOxNEDPxE1?	NEHWbI04OiCq	NEnmXZNFVVOR	MY\JR\|UxRTFyIN88US=>	NYO2fFJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H460	NVfvTFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nzZVExKM7:TR?=	NUG4ZoxyPzJiaB?=	MlzUSG1UVw>?	NXHWRnd7UUN3ME2xNEDPxE1?	NGfhN3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Calu-6	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPwU4VYOTBizszN	MWW3NkBp	NXW5Ro1TTE2VTx?=	NVL1TWdDUUN3ME2xNEDPxE1?	NHLheWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HCC-2998	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4K1cVExKM7:TR?=	NIDjbWw4OiCq	M3Oy[GROW09?	NU\hOIdJUUN3ME2xNEDPxE1?	NIjwNW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
LS1034	NIXwXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjCNVAh\|ryP	NU\VZ2F2PzJiaB?=	M3HCXWROW09?	MmjETWM2OD1zMDFOwG0>	NWjYSVJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CHP-212	Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYixb4lwOTBizszN	MYK3NkBp	NFjafoZFVVOR	MWrJR\|UxRTFyIN88US=>	NUDCOodVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-N-AS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXSxNEDPxE1?	NYrNdoxQPzJiaB?=	M37tdmROW09?	MnfnTWM2OD1zMDFOwG0>	MmXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
BFTC-905	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3UNVAh\|ryP	MWi3NkBp	NYqwVJpNTE2VTx?=	NUT6SpBDUUN3ME2xNEDPxE1?	NFPTSlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HuT78	NGLtbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DpSVExKM7:TR?=	NF3GcYI4OiCq	MYDEUXNQ	NGPXWVZKSzVyPUWyJI5O	NFvoZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
RPMI-8226	NF3CTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInodFYyOCEQvF2=	NYfCR2w4PzJiaB?=	NGfwfHZFVVOR	Ml\MTWM2OD1{NkOgcm0>	NXrINlU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BC-3	M1noS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnITooyOCEQvF2=	MmjJO\|IhcA>?	MUPEUXNQ	NUWySYpNUUN3ME2yO\|chdk1?	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ACHN	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrEdmMyOCEQvF2=	MlGwO\|IhcA>?	MknqSG1UVw>?	NVz5NlNHUUN3ME2yPVQhdk1?	MlvvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
JRT3-T35	NV[0PYprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\hUoY3OTBizszN	MUS3NkBp	NVPOSJFtTE2VTx?=	NIfw[2pKSzVyPUK5OUBvVQ>?	MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-MES-1	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuxNEDPxE1?	MlPkO\|IhcA>?	M4TBSGROW09?	M1nWdGlEPTB;M{K5JI5O	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CESS	NWjFOnZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknyNVAh\|ryP	MVi3NkBp	MVHEUXNQ	MYPJR\|UxRTR7NzDuUS=>	M4rjS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
H4	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HzV\|ExKM7:TR?=	M{ThXFczKGh?	NWL6boFETE2VTx?=	Mor6TWM2OD14MUmgcm0>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
BC-1	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXWxNEDPxE1?	NInVRVA4OiCq	NGTXSWhFVVOR	NGLrd49KSzVyPUewOEBvVQ>?	MmftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DB	M{XjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHTNnIyOCEQvF2=	MWG3NkBp	NFv6O5ZFVVOR	MkP1TWM2OD16N{Ogcm0>	NWLiR5BbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
RPMI-6666	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;I[XcyOTBizszN	MXK3NkBp	M1\vU2ROW09?	NWHiUJluUUN3ME25Nlghdk1?	M{\DO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MC/CAR	NE\ud5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fwR\|ExKM7:TR?=	MkfyO\|IhcA>?	NHLNNolFVVOR	NGLVcY9KSzVyPUGuNFAzKM7:TR?=	MmC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-1	NGL5WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnm0NVAh\|ryP	M{TNUlczKGh?	NYfscGZRTE2VTx?=	Mmn4TWM2OD1zLkWwNUDPxE1?	MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CEM/C1	NUi3ZlZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUixNEDPxE1?	NITOVIs4OiCq	MoXvSG1UVw>?	NF2wN2JKSzVyPUGuO\|c{KM7:TR?=	NIj4UYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
GDM-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDlZW8yOCEQvF2=	MlzNO\|IhcA>?	MWjEUXNQ	NIKwUlJKSzVyPUGuPVk4KM7:TR?=	NULLcJI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HT-1080	M1rwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LreFExKM7:TR?=	MVO3NkBp	M1nwWWROW09?	Mk\0TWM2OD1{LkCwOEDPxE1?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HL-60	NHzodXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLObo1QOTBizszN	NWrkZpRFPzJiaB?=	MXrEUXNQ	MnPWTWM2OD1{LkG3PEDPxE1?	NUDReWM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
C3A	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3u[IhFOTBizszN	MXe3NkBp	M1vBemROW09?	M3HOc2lEPTB;NT60NVQh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MES-SA	NXXpOYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\mNVAh\|ryP	M2XQWVczKGh?	NFjaWJdFVVOR	NEDmfpBKSzVyPU[uPVg6KM7:TR?=	M33hfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
22Rv1	NVXXbnJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqxNEDPxE1?	NXnxZY9iPzJiaB?=	NHe2RpFFVVOR	MYDJR\|UxRTFyIN88US=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
647-V	M4TyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUKxNEDPxE1?	MXS3NkBp	M4DqWGROW09?	Mn\BTWM2OD1zMDFOwG0>	NIG4NlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
786-O	Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnHNVAh\|ryP	NG\mN4s4OiCq	NFyxepdFVVOR	NXXXTFc1UUN3ME2xNEDPxE1?	M{O2TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A172	M4O4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmxNEDPxE1?	NWLPdohkPzJiaB?=	NWPW[pY4TE2VTx?=	NY\s[Y9VUUN3ME2xNEDPxE1?	MonlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A204	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX6zS4JlOTBizszN	MY[3NkBp	NGH0WHZFVVOR	MoT4TWM2OD1zMDFOwG0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A427	NGnMZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX[xNEDPxE1?	NFfLdGg4OiCq	MVrEUXNQ	NF;2fpBKSzVyPUGwJO69VQ>?	NGOzenQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A431	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;HO3lrOTBizszN	NFvCWHU4OiCq	M1PwOmROW09?	NVqz[4RHUUN3ME2xNEDPxE1?	MlXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A2780	NHKwWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NImxSJQyOCEQvF2=	NWHZT\|FYPzJiaB?=	MVzEUXNQ	MmPxTWM2OD1zMDFOwG0>	Mlz2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ARH-77	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HNWFExKM7:TR?=	MXe3NkBp	NE[wcpBFVVOR	M120VmlEPTB;MUCg{txO	NI\6NYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Be(2)C	NFTBeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\2T4syOCEQvF2=	MnrTO\|IhcA>?	NYjyUocxTE2VTx?=	MmPmTWM2OD1zMDFOwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
BT-20	NYj4eVBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzqNVAh\|ryP	NIn1d3Q4OiCq	M2LKbWROW09?	MXrJR\|UxRTFyIN88US=>	MnfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
BxPc3	NGjWU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3VSIxvOTBizszN	MkXqO\|IhcA>?	MX\EUXNQ	M1LB[GlEPTB;MUCg{txO	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
C-4 I	NInQbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3mzVVExKM7:TR?=	MlvVO\|IhcA>?	NUfSW\|Y{TE2VTx?=	NU\rRYpjUUN3ME2xNEDPxE1?	M4PaNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
C33A	NX22dI9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSxNEDPxE1?	NIDYZYk4OiCq	NXPqU3hFTE2VTx?=	NHvmem1KSzVyPUGwJO69VQ>?	MkHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CAL-27	M3jFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[2WFExKM7:TR?=	NV7FdlhqPzJiaB?=	MUDEUXNQ	MYjJR\|UxRTFyIN88US=>	MljlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CAL-62	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNEDPxE1?	NHX3cmI4OiCq	NILSOJVFVVOR	M3ezWGlEPTB;MUCg{txO	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Calu-3	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNEDPxE1?	Ml31O\|IhcA>?	NV3aSotkTE2VTx?=	NYPlOZZtUUN3ME2xNEDPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CaOV3	NH;rXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn70NVAh\|ryP	NIG1U2E4OiCq	MlTvSG1UVw>?	MUfJR\|UxRTFyIN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CGTHW1	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zEWlExKM7:TR?=	M4TTOVczKGh?	NIf5[oZFVVOR	M{nHWWlEPTB;MUCg{txO	NHvMdoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CHL-1	NIjQSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTRNVAh\|ryP	NVf4PId[PzJiaB?=	NWHKPJkyTE2VTx?=	NVfnfGNXUUN3ME2xNEDPxE1?	NX\RcVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Colo320DM	NI\UVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNEDPxE1?	MljBO\|IhcA>?	MYfEUXNQ	NYmyZ4dpUUN3ME2xNEDPxE1?	M{XpOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Colo704	NE[4NYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XXPFExKM7:TR?=	NXnjN45RPzJiaB?=	MWrEUXNQ	NUXkbpNWUUN3ME2xNEDPxE1?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
COR-L23	M4XtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\vbZg5OTBizszN	MXq3NkBp	MlfXSG1UVw>?	NU\3OnBKUUN3ME2xNEDPxE1?	M4nDV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CRO-AP2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPYNVcyOCEQvF2=	MkHkO\|IhcA>?	M3nISWROW09?	MYHJR\|UxRTFyIN88US=>	NGPB[nA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Daudi	M1:xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHntW24yOCEQvF2=	NVTzVXlRPzJiaB?=	MnLmSG1UVw>?	MUDJR\|UxRTFyIN88US=>	M3LIOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DOTC 24510	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPreZcyOCEQvF2=	NGHpeZI4OiCq	NUPmSnpMTE2VTx?=	MYrJR\|UxRTFyIN88US=>	M2G3VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DU-145	M3q2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXBNVAh\|ryP	MUK3NkBp	MYHEUXNQ	MXnJR\|UxRTFyIN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
EB-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXqxNEDPxE1?	M4XDXlczKGh?	MlrDSG1UVw>?	M{C1Z2lEPTB;MUCg{txO	NVPvVWp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
EFM-19	NVOycXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXJXYhWOTBizszN	NX7oOHE2PzJiaB?=	NUT0[ZNvTE2VTx?=	NWjNUmVuUUN3ME2xNEDPxE1?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
EKVX	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXrNVAh\|ryP	NFrIOms4OiCq	MYfEUXNQ	MX7JR\|UxRTFyIN88US=>	NVXrXWd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
FaDu	NF;G[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW[xNEDPxE1?	NYfMeGRGPzJiaB?=	MkX5SG1UVw>?	MVrJR\|UxRTFyIN88US=>	NEj5cmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
G401	NWO4d4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWqwbpQ{OTBizszN	MVS3NkBp	MYTEUXNQ	NVixOWxDUUN3ME2xNEDPxE1?	M{[zd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HCC-70	NGnGW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\KW\|ExKM7:TR?=	Mn:1O\|IhcA>?	MXjEUXNQ	NFWydY5KSzVyPUGwJO69VQ>?	MnTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HCC-1954	M1jSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUexNEDPxE1?	MVG3NkBp	NUjHfHdFTE2VTx?=	M2rQZWlEPTB;MUCg{txO	NXOxSWxNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Hela	Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPueYM3OTBizszN	MUW3NkBp	M2jTbmROW09?	MYfJR\|UxRTFyIN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Hep3B	NV7YWXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXuxNEDPxE1?	NFLYbVM4OiCq	NI\U[ZJFVVOR	NV65TI5wUUN3ME2xNEDPxE1?	M4DxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HMCB	NXvQXoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTDNVAh\|ryP	M4jIR\|czKGh?	NWXzZWlwTE2VTx?=	MVvJR\|UxRTFyIN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HN5	NWC1OlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nsO\|ExKM7:TR?=	M1PQeFczKGh?	NF6zWXhFVVOR	M1nN[WlEPTB;MUCg{txO	NXfkcW1DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HOS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLobGtkOTBizszN	M3\rXFczKGh?	MWHEUXNQ	MVzJR\|UxRTFyIN88US=>	NYn1XnI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HPAF-II	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\uUGdkOTBizszN	M1iwSVczKGh?	MmHlSG1UVw>?	MlGwTWM2OD1zMDFOwG0>	M3vjZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Hs746.T	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnC[oEyOCEQvF2=	NGPTeG04OiCq	MmrVSG1UVw>?	MX7JR\|UxRTFyIN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HT	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGxNEDPxE1?	M{mxc\|czKGh?	M1[4NmROW09?	MV\JR\|UxRTFyIN88US=>	NHLXbXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HT-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\3NVAh\|ryP	NEL3NXE4OiCq	NH6xR5VFVVOR	Mny5TWM2OD1zMDFOwG0>	NGrJXlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HuNS-1	NITGW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3:4WlExKM7:TR?=	NFTVSVg4OiCq	MUXEUXNQ	M{fyU2lEPTB;MUCg{txO	NUTSfFlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
IGROV1	M{\kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\YNVAh\|ryP	NXjCSm9CPzJiaB?=	NYDURYl7TE2VTx?=	MULJR\|UxRTFyIN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
J82	NHPuNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvlWGQyOCEQvF2=	M2SwRlczKGh?	M3uwW2ROW09?	M2HNVWlEPTB;MUCg{txO	M1T2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
JM1	M37JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXlNVAh\|ryP	NYL2c2tFPzJiaB?=	M2T3bmROW09?	NEjST3FKSzVyPUGwJO69VQ>?	NGXafpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Kato III	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXSye2pDOTBizszN	MoWyO\|IhcA>?	NWXPdGFrTE2VTx?=	MXHJR\|UxRTFyIN88US=>	M13TNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KHOS-240S	NYnlbHNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCxNEDPxE1?	MUm3NkBp	MUDEUXNQ	MoD4TWM2OD1zMDFOwG0>	MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
KM-12	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIT2RVAyOCEQvF2=	M2C0flczKGh?	MWTEUXNQ	NWTERWhrUUN3ME2xNEDPxE1?	MkGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
KPL-1	M2PrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHrdpJNOTBizszN	M4nhXFczKGh?	MofxSG1UVw>?	MVnJR\|UxRTFyIN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KYSE-30	NFfWVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rOc\|ExKM7:TR?=	NGDWd5o4OiCq	M4rnSGROW09?	M2OwR2lEPTB;MUCg{txO	NFPF[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
LNCaP	NXzVPYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPkNVAh\|ryP	NWjFbHlXPzJiaB?=	M4mzSWROW09?	NWnYdIN3UUN3ME2xNEDPxE1?	NGjLc5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MCF-7	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrjNVAh\|ryP	MmfkO\|IhcA>?	NFK0OHlFVVOR	MlWwTWM2OD1zMDFOwG0>	Mn[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MC-IXC	NVLhU\|JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n2dVExKM7:TR?=	M3fFTlczKGh?	NXXLPVBmTE2VTx?=	NWLmb3NCUUN3ME2xNEDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MDA-MB-175 VII	NEXHT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXyxNEDPxE1?	M4HYclczKGh?	NHrQb3FFVVOR	MVvJR\|UxRTFyIN88US=>	NHfybHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MDA-MB-468	NW[3TnJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rRe\|ExKM7:TR?=	NIr1TYw4OiCq	Mo\QSG1UVw>?	NYjBWG0yUUN3ME2xNEDPxE1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MiaPaCa	NGfvNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDNem8yOCEQvF2=	NGr4[Y84OiCq	NWLYcHNGTE2VTx?=	NUTYd5ZQUUN3ME2xNEDPxE1?	NXK0cXB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Molt-4	M1u3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUixNEDPxE1?	NHrERYQ4OiCq	MV;EUXNQ	NWn6[Xo2UUN3ME2xNEDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-ADR/RES	NETac3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfxNVAh\|ryP	M1rxTVczKGh?	MoPWSG1UVw>?	M{f2dGlEPTB;MUCg{txO	NWLmTnpDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H69	M{Lu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUCxNEDPxE1?	NETCRXc4OiCq	MUHEUXNQ	NX7qU\|dNUUN3ME2xNEDPxE1?	NGnZNFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H82	NVHWWXVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHSNVAh\|ryP	MVK3NkBp	MmXVSG1UVw>?	MmPiTWM2OD1zMDFOwG0>	NWTXW4VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-N87	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PqSVExKM7:TR?=	MoTBO\|IhcA>?	M{PrT2ROW09?	NFrRWWNKSzVyPUGwJO69VQ>?	M3;GNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H146	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYCxNEDPxE1?	NWrjT2xJPzJiaB?=	M3rtTmROW09?	MkPDTWM2OD1zMDFOwG0>	NHjydms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H157	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjuNVAh\|ryP	MVO3NkBp	NHfWbWZFVVOR	M2LBOGlEPTB;MUCg{txO	M{i3PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H187	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLjN2tNOTBizszN	MWe3NkBp	NWXQcW9JTE2VTx?=	M{LHOGlEPTB;MUCg{txO	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H209	NHrOcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPLToMyOCEQvF2=	NUnkOXlkPzJiaB?=	NVXl[VJITE2VTx?=	MmPNTWM2OD1zMDFOwG0>	NFXTNJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H226	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvtOpo1OTBizszN	MmfhO\|IhcA>?	MY\EUXNQ	NITpbmpKSzVyPUGwJO69VQ>?	NV3Pb\|c1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H292	NUL2Z4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3tNVAh\|ryP	MYO3NkBp	M{TWU2ROW09?	NVHjUnNOUUN3ME2xNEDPxE1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H322	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HWR\|ExKM7:TR?=	M4nTUlczKGh?	NHjEcmZFVVOR	MX\JR\|UxRTFyIN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H358	NU[0d3BGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7iRVMyOCEQvF2=	NEnFe5I4OiCq	MXjEUXNQ	MkHiTWM2OD1zMDFOwG0>	NFeze3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H520	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\ZZokyOCEQvF2=	M1vsOVczKGh?	NHz6OJVFVVOR	MmiyTWM2OD1zMDFOwG0>	NYTXTI81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H526	NVfISGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXixNEDPxE1?	MlrwO\|IhcA>?	M{TG[GROW09?	M{nWfmlEPTB;MUCg{txO	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H630	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjkfIIyOCEQvF2=	MV:3NkBp	M1HyR2ROW09?	M2XwWmlEPTB;MUCg{txO	NFe0c\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H661	NWf3foY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXHSXAyOCEQvF2=	NY\DN3lwPzJiaB?=	MUfEUXNQ	M1L2UGlEPTB;MUCg{txO	NHrQdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H716	M2jT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmP5NVAh\|ryP	M1yyb\|czKGh?	MUDEUXNQ	NXzwcYE2UUN3ME2xNEDPxE1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H1563	NH\idoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr1fngyOCEQvF2=	NYfrTolzPzJiaB?=	MlT5SG1UVw>?	NXS1fZpRUUN3ME2xNEDPxE1?	NXTTWHByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H1792	NYrzTmlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUixNEDPxE1?	MnfvO\|IhcA>?	MnjMSG1UVw>?	MULJR\|UxRTFyIN88US=>	NXvUOo0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H2030	NV[4dWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfCNIYyOCEQvF2=	MUC3NkBp	Ml;mSG1UVw>?	NEDHW4lKSzVyPUGwJO69VQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H2052	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fR[VExKM7:TR?=	NH;sSVQ4OiCq	M3rKb2ROW09?	NX[0VIlwUUN3ME2xNEDPxE1?	NUf2UZRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H2122	M3jiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX0Z3AyOCEQvF2=	MYG3NkBp	MXjEUXNQ	NX3TXY12UUN3ME2xNEDPxE1?	M{HIWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H2228	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmxNEDPxE1?	NGXqVHU4OiCq	M2CwR2ROW09?	NF\L[JZKSzVyPUGwJO69VQ>?	M1qzWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OE-19	M3;2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPNeYoyOTBizszN	NWLiVpFKPzJiaB?=	NYPwNZdnTE2VTx?=	MmDiTWM2OD1zMDFOwG0>	Ml;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
OE-21	NF7SN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;aRpVHOTBizszN	MVK3NkBp	MXLEUXNQ	NV3ON41zUUN3ME2xNEDPxE1?	NGL1eWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OE-33	NGXaSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLYNVAh\|ryP	MoXNO\|IhcA>?	M3XrO2ROW09?	NVrjU4doUUN3ME2xNEDPxE1?	NVrS[JVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OVCAR-3	NF\DTXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXKNVAh\|ryP	MmrDO\|IhcA>?	MWHEUXNQ	M2jSXmlEPTB;MUCg{txO	M2fpfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-4	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zmeFExKM7:TR?=	NIXrWFU4OiCq	MUHEUXNQ	NVPsfWhmUUN3ME2xNEDPxE1?	NYrIR4tSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OVCAR-5	M3P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPaNVAh\|ryP	NGj0Nmo4OiCq	NF;JZYVFVVOR	Ml\zTWM2OD1zMDFOwG0>	MkjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
P3HR-1	M{HJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT2[Vd5OTBizszN	NHP1dpo4OiCq	M4r6c2ROW09?	MVPJR\|UxRTFyIN88US=>	NFjZZmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
PC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXxd2dJOTBizszN	M13ab\|czKGh?	NXjVR\|lvTE2VTx?=	MlTPTWM2OD1zMDFOwG0>	NEPJOYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Raji	NWT6OYRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHSR4IyOCEQvF2=	NVvXbIpqPzJiaB?=	MlPUSG1UVw>?	NEfyVYhKSzVyPUGwJO69VQ>?	MnGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RD	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYC1dVlKOTBizszN	MoHOO\|IhcA>?	NWfxO4FITE2VTx?=	MYPJR\|UxRTFyIN88US=>	M2O2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RD-ES	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f6elExKM7:TR?=	M2HySFczKGh?	M1\ic2ROW09?	NXz6PZVMUUN3ME2xNEDPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RL	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXkNVAh\|ryP	M1LDWFczKGh?	M{XYUGROW09?	MonDTWM2OD1zMDFOwG0>	NIi4UGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SaOS2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\KcFExKM7:TR?=	NFzVN2s4OiCq	M37qTmROW09?	NH7LSWtKSzVyPUGwJO69VQ>?	NH65dJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCC-9	M3jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPpNVAh\|ryP	M1qyUVczKGh?	NWO0e\|dGTE2VTx?=	MkDyTWM2OD1zMDFOwG0>	M1PzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-12	M3P6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjTW4JSOTBizszN	Mm\EO\|IhcA>?	MYPEUXNQ	M2TUbGlEPTB;MUCg{txO	M{fpVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-13	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TuTlExKM7:TR?=	NGiwVYg4OiCq	NWfpV4FiTE2VTx?=	M17CO2lEPTB;MUCg{txO	M4nDSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-15	M3[5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXhNVAh\|ryP	MXS3NkBp	NGrVdGhFVVOR	MUTJR\|UxRTFyIN88US=>	MkiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-25	NIn0TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TObFExKM7:TR?=	NXT0fGRmPzJiaB?=	M2fLd2ROW09?	M4\MdWlEPTB;MUCg{txO	MlfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCLC-3	NWXnXpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvUb4l[OTBizszN	MnrvO\|IhcA>?	NGm0VnlFVVOR	M1TJXWlEPTB;MUCg{txO	NInqW\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SF-268	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\r[\|ExKM7:TR?=	NX[4[FJkPzJiaB?=	MWHEUXNQ	M4\oTmlEPTB;MUCg{txO	NUPBO2F5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SF-295	MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWOxNEDPxE1?	MnfiO\|IhcA>?	MUHEUXNQ	M1mwTmlEPTB;MUCg{txO	NELTbpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SJRH30	NYDBeJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXWxNEDPxE1?	MU[3NkBp	MmnvSG1UVw>?	NHXxXlNKSzVyPUGwJO69VQ>?	NUHxO5hZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-BR-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfZ[\|dNOTBizszN	MUO3NkBp	MVTEUXNQ	MUnJR\|UxRTFyIN88US=>	NXznblVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-LMS-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPJSmMyOCEQvF2=	MYq3NkBp	NUfsPWdKTE2VTx?=	MojrTWM2OD1zMDFOwG0>	M4XmZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-DZ	M2nwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGxNEDPxE1?	MnXEO\|IhcA>?	NV3rWXhkTE2VTx?=	NGO0ZldKSzVyPUGwJO69VQ>?	NHuzSVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-N-F1	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LKZVExKM7:TR?=	Mn3QO\|IhcA>?	MXfEUXNQ	MmfMTWM2OD1zMDFOwG0>	NWrPWJUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SKOV-3	NXn3PYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K5OVExKM7:TR?=	MX:3NkBp	M3L5RmROW09?	NGHqN2lKSzVyPUGwJO69VQ>?	NIHLS4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-UT-1	NFPRflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYC3bYpPOTBizszN	NUm3OXNYPzJiaB?=	MVPEUXNQ	MkL3TWM2OD1zMDFOwG0>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SN12C	NViwV\|BqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzoNVAh\|ryP	M3S4cFczKGh?	Ml3hSG1UVw>?	NInYPY1KSzVyPUGwJO69VQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SNB-19	M3LjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[0SIRbOTBizszN	M2i3eFczKGh?	MkezSG1UVw>?	MlTnTWM2OD1zMDFOwG0>	M4jHU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SNU-5	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUixNEDPxE1?	M37LRlczKGh?	NHm3RXpFVVOR	MVXJR\|UxRTFyIN88US=>	Mm\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-16	M1zEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrnRol3OTBizszN	M{XkVlczKGh?	MmPvSG1UVw>?	Mmj6TWM2OD1zMDFOwG0>	MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-398	M1TEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTMc4ZyOTBizszN	NE\rWYk4OiCq	MmrnSG1UVw>?	MYrJR\|UxRTFyIN88US=>	M4rVZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SNU-449	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1u4NFExKM7:TR?=	MVy3NkBp	NEHhU4JFVVOR	NWjNOokzUUN3ME2xNEDPxE1?	Mom4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SR	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLYOo8yOCEQvF2=	NEPuWlE4OiCq	NXLGUI5NTE2VTx?=	NIG4OHRKSzVyPUGwJO69VQ>?	NEHWcFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ST486	M3XSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\xTlExKM7:TR?=	M17hSFczKGh?	MYHEUXNQ	MkLwTWM2OD1zMDFOwG0>	M1XJbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW579	M4e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXyxNEDPxE1?	M1W0TFczKGh?	M1H1UWROW09?	MV;JR\|UxRTFyIN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW684	NWrmVphGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWixNEDPxE1?	MWi3NkBp	NYXLSnhTTE2VTx?=	MlGxTWM2OD1zMDFOwG0>	M123PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-780	M{H1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVKxNEDPxE1?	NF2zSHM4OiCq	NUP1U4M{TE2VTx?=	M4e0[WlEPTB;MUCg{txO	NELYPZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW900	NYrOR494T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:xNEDPxE1?	MXO3NkBp	NGryelFFVVOR	NG[yZ25KSzVyPUGwJO69VQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1088	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;Tb\|ExKM7:TR?=	MlH0O\|IhcA>?	MlvjSG1UVw>?	M3\PT2lEPTB;MUCg{txO	NYjYW2N3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW1463	M{T4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nxVlExKM7:TR?=	MoThO\|IhcA>?	MoThSG1UVw>?	MWjJR\|UxRTFyIN88US=>	NXjiWopjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW1990	NXvnbI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLQNVAh\|ryP	MlrIO\|IhcA>?	NVLMUldVTE2VTx?=	NY[2PZFjUUN3ME2xNEDPxE1?	NGrkPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
T47D	NHOzNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v3O\|ExKM7:TR?=	MXq3NkBp	NFLobG9FVVOR	MnrVTWM2OD1zMDFOwG0>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
TE381.T	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHG4XnIyOCEQvF2=	NWDpSok3PzJiaB?=	M3K3U2ROW09?	M1fFSmlEPTB;MUCg{txO	NYfpVoRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
TK-10	NVHmS3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LKTVExKM7:TR?=	M2DnXFczKGh?	MXLEUXNQ	MlXtTWM2OD1zMDFOwG0>	NIn4PXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
U2OS	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHv[WEyOCEQvF2=	NIHhWFA4OiCq	NGDtZ2lFVVOR	M3uzZ2lEPTB;MUCg{txO	M1Xa[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
U251	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorwNVAh\|ryP	NUPybYRoPzJiaB?=	M2ewUmROW09?	MVXJR\|UxRTFyIN88US=>	NV7BRZhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UACC-812	MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnWxNVAh\|ryP	NGjmdW84OiCq	MmDzSG1UVw>?	NWHUdVRSUUN3ME2xNEDPxE1?	NWTk[mJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
YAPC	NWDlcWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK4XmIyOCEQvF2=	M2DKV\|czKGh?	MonySG1UVw>?	NFz0NnZKSzVyPUGwJO69VQ>?	MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ZR-75-1	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHtUI4yOCEQvF2=	MkLKO\|IhcA>?	Mn\rSG1UVw>?	NVTVc5VVUUN3ME2xNEDPxE1?	Mk\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A375	NV7XNVZTTnWwY4Tpc44h[XO\|YYm=	M3O4eFEvOiEQvF2=	NX:wVHlvPCCq	MlrVSG1UVw>?	MlHpTY5pcWKrdHnvckBw\iCyaH;zdIhwenmuYYTpc44hd2ZiTVXLMEBGWktuIHHu[EBUPlB?	NFrMe5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO4PVQ4OSd-MkKzPFk1PzF:L3G+
YUSIT1	M3i3S2Z2dmO2aX;uJIF{e2G7			M164VmROW09?	NH[wTY5z\WS3Y3XkJJNmdnOrdHn2bZR6KHerdHigTWM2OCB-IECuOUDPxE1?	M133e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{i5OFcyLz5{MkO4PVQ4OTxxYU6=
MeWo	M{PWdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MWnEUXNQ	M2LSb2lEPTBiPTC5PFchdk1?	NELSNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCxPFUzPCd-Mk[wNVg2OjR:L3G+
WiDr	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NETYRmNFVVOR	NXG2VGV[UUN3MDC9JFc3KG6P	NUHJ[JU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVg2OjRpPkK2NFE5PTJ2PD;hQi=>
Colo-205	MnLESpVv[3Srb36gZZN{[Xl?	Mk\KNUDPxE1?	NX3KZVlzPCCm	MkPHSG1UVw>?	NHG1dGJKdmS3Y3XkJIEhcGmpaHz5JINwdXCjcnHicIUh[2:vcHHjeIlwdiCyaHXuc5R6eGV?	NIXUUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO4NVE2Oid-MkWzPFEyPTJ:L3G+
RBW-1	M1G0ZWZ2dmO2aX;uJIF{e2G7	NXL2OW9xOSEQvF2=		Ml\0SG1UVw>?	MVHOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
RBO-1	NGCwRVRHfW6ldHnvckBie3OjeR?=	NGPtV2YyKM7:TR?=		NIW2TmRFVVOR	NVTwTml[UW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEW2PVAoRjJ2OEi1OlkxRC:jPh?=
RBO-2	NIH1VZdHfW6ldHnvckBie3OjeR?=	M1zlfVEh\|ryP		MnTJSG1UVw>?	NHXBOlBKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>?	NUDzO2JjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFU3QTBpPkK0PFg2PjlyPD;hQi=>
RBOW	NYPTN2xYTnWwY4Tpc44h[XO\|YYm=	NV7FcZh5OSEQvF2=		MWXEUXNQ	MlvOTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	Mn;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEW2PVAoRjJ2OEi1OlkxRC:jPh?=
M257	M{DzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPoNVAxKG6P	M4TPPVczKGh?		NFHEeG1Fd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NXPT[VBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
LCP	M2XqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jZWlExOCCwTR?=	NWjzRlF7PzJiaB?=		NEP6fnlKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	NGLTWHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
WM266	NHLubZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULKclJVOTByIH7N	Mlm1O\|IhcA>?		MVTJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhX01{Nk[gZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMVSgcZV1[W62YYTpc44>	NYnRd5F2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
M257	NYrpO\|ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPPO2xoOTByIH7N	MUC3NkBp		M2LpZWRw\XNibn;0JIlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	MmXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
LCP	MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnz[GgyODBibl2=	NHj1SWw4OiCq		NVjkSIk5UW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJGxEWCClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxWiCvdYThcpRifGmxbh?=	NV7QbHMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
WM266	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTuVY5mOTByIH7N	Ml34O\|IhcA>?		Ml;UTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w	NInYd3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
A375	NWrKcoxVSlKDRjDjc41x\XSrdHn2[UBjcW6maX7nJIF{e2G7		NIHlSXcyPSCvaX6=		M2jqS2lEPTBiPTCwMlAxPiEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
A375	NULxUYFHTnWwY4Tpc44h[XO\|YYm=		NYLQRlkxPzJiaB?=		NV30W3BXUUN3MDC9JFAvODFzIN88US=>	Mnz1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	M2PvcGFTSUZiY3;tdIV1cXSrdnWgZolv\GmwZzDhd5NigQ>?		M4fzXFE2KG2rbh?=		MYfJR\|UxKD1iMD6wNlYh\|ryP	M1nDVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
A375	MmPPR3JCTiClb33w[ZRqfGm4ZTDibY5lcW6pIHHzd4F6		NX:2O4Z3OTVibXnu		NHLLUIRKSzVyIE2gNE4yPSEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
HCT116	M2LKVmZ2dmO2aX;uJIF{e2G7				NUDZbmtyUUN3MDC9JFUvQDhizszN	NVuzWplQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	Mn21SpVv[3Srb36gZZN{[Xl?		MnexNUBp		M{LKbWlEPTBiPTCwMlAxOSEQvF2=	MoHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyOEW2O\|IoRjJ5MEi1OlczRC:jPh?=
MIAPaCa2	NHLYfWhHfW6ldHnvckBie3OjeR?=		MoOxNUBp		Ml[wSWM2OCB;IECuOVI6KM7:TR?=	M121VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi1OlczLz5{N{C4OVY4OjxxYU6=
A375	NF30XmtHfW6ldHnvckBie3OjeR?=				NFy2WmZKSzVyIE2gNE4xODRizszN	NFW1e\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2NVgzPyd-Mkm0OlE5Ojd:L3G+
SK-MEL-28	Mnv2R5l1d3SxeHnjbZR6KGG\|c3H5		MUK3NkBp		NIniO3JKSzVyIE2gNE4xPDNizszN	MnzVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
Sf9	MnzFSpVv[3Srb36gZZN{[Xl?		MXm2NEBucW5?		MXPJR\|UxKD1iMD6wNFkh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGzO{c,Ojd5N{SxN\|c9N2F-
SK-MEL-28	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2jKc\|Q5KGh?		NWP1W4ZZT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBu\WG\|dYLl[EBi\nSncjC0PEBpenNicnXzZZp2emmwIHHzd4F6	NID1bHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{Pyd-Mke3O\|QyOzd:L3G+
SK-MEL-28	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn3jOFghcA>?		MVjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiaHHyZo9zcW6pIFLSRWYhXjZyMFWgcZV1[W62IIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSCrcoLh[IlifGmxbjDv[kAyNjF\|IHvXM40zKFWYLXzp[4h1KG[xcjC1JI1qdnNibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJJJme2G8dYLpckBie3OjeR?=	M1TPUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
SK-MEL-28	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=		Ml7MOFghcA>?		Mk\PR5l1d3O2YYTpZ{Bi[3Srdnn0fUBqdiCqdX3hckBUUy2PRVytNlgh[2WubIOgbIFz[m:{aX7nJGJTSUZiVk[wNGUhdXW2YX70JIF1KDFiYX7kJFMxKHWPIH3lZZN2emWmIHHmeIVzKDR6IHjyd{Bz\XOjeoXybY4h[XO\|YYm=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGzO{c,Ojd5N{SxN\|c9N2F-
DAOY	MU\Qdolu[XK7IIPjdoVmdiCjc4PhfS=>				MnnodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NYHHNVNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NYfUTnVHWHKrbXHyfUB{[3KnZX6gZZN{[Xl?				M13yc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MnvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NEnUNpBRemmvYYL5JJNkemWnbjDhd5NigQ>?				M{m2WZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MlvvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	GSK2118436A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04547946	Not yet recruiting	Drug: dabrafenib + trametinib	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	January 29 2021	--
NCT04666272	Not yet recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	December 22 2020	--
NCT04452877	Recruiting	Drug: Dabrafenib\|Drug: Trametinib	Carcinoma Non-Small-Cell Lung	Novartis Pharmaceuticals\|Novartis	August 19 2020	Phase 2
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib (BAY 43-9006)

Sorafenib (BAY 43-9006, NSC-724772) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib (BAY 43-9006) tosylate

Sorafenib (BAY 43-9006) tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)